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ABSTRACT
Dermal neurofibromas (DNFs) are benign peripheral nerve sheath tumors
thought to originate from Schwann cell progenitors. These tumors represent one of
the hallmarks of the neurofibromatosis type 1 (NF1) tumor predisposition syndrome,
where they can number in the thousands. While NF1-DNFs arise due to mutations
in the NF1 gene, the vast majority of DNFs occur sporadically (sp-DNFs), where the
genetic etiology is currently unknown. Herein, we employed whole-exome sequencing
of sp-DNFs to identify a recurrent mutation in the KIR2DL5 gene, which codes for a
protein suppressor of natural killer (NK) cell activity. While the function of KIR2DL5
outside of the immune system is unknown, we identified a KIR2DL5N173D mutation in
three of nine sp-DNFs, resulting in loss of KIR2DL5 protein expression. In contrast, two
of these subjects had unrelated tumors, which retained KIR2DL5 protein expression.
Moreover, loss of KIR2DL5 expression was demonstrated in 15 of 45 independentlyidentified sp-DNFs. Consistent with its potential role as a negative growth regulator
important for neurofibroma maintenance, ectopic KIR2DL5N173D expression in normal
human Schwann cells resulted in reduced KIR2DL5 expression and increased cell
proliferation. Similarly, KIR2DL5 short hairpin RNA knockdown (KD) decreased
KIR2DL5 protein levels and increased cell proliferation, as well as correlated with
PDGFRβ and downstream RAS/AKT/mTOR hyperactivation. Importantly, inhibition
of PDGFRβ or AKT/mTOR activity in KIR2DL5-KD human Schwann cells reduced
proliferation to control levels. Collectively, these findings establish KIR2DL5 as a new
Schwann cell growth regulator relevant to sp-DNF pathogenesis, which links sporadic
and NF1-associated DNFs through RAS pathway hyperactivation.

INTRODUCTION

NF1 loss reflects a combination of a germline NF1 gene
mutation and the acquisition of a somatic NF1 mutation
in Schwann cell lineage populations [3, 4]. As a RASGTPase-activating protein (RAS-GAP), neurofibromin
loss in Schwann cells leads to increased RAS activation
[8–10] and downstream mechanistic target of rapamycin
(mTOR)-mediated hyperproliferation [11–14].
While NF1 mutations characterize NF1-DNFs, the
majority of DNFs occurs in the absence of NF1. These
sporadic DNFs (sp-DNFs) are histologically identical to
their NF1-associated counterparts, and most often arise as
solitary dermal tumors. Since these tumors are encountered
in individuals lacking other features supportive of a

Dermal neurofibromas (DNFs) are common lowgrade peripheral nerve sheath tumors [1], which are
hypothesized to arise from Schwann cell progenitors
[2–4]. While these tumors do not undergo malignant
transformation, they can be painful or number
in the thousands, as seen in some adults with the
neurofibromatosis type 1 (NF1; OMIM: 613113) cancer
predisposition syndrome. Nearly all adults with NF1
manifest DNFs, which result from bi-allelic inactivation
of the NF1 tumor suppressor gene and loss of NF1
protein (neurofibromin) expression [5–7]. This bi-allelic
www.impactjournals.com/oncotarget
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clinical diagnosis of NF1, they do not harbor NF1 gene
mutations. As such, it is currently not known what genetic
mutations are responsible for the genesis of sp-DNFs. In
an effort to identify potential molecular etiologies for these
non-syndromal benign nerve sheath tumors, we performed
whole exome sequencing on a series of NF1-associated
and sporadic dermal neurofibromas.

immunoglobulin-like domain [25] (Supplementary
Figure 3A). In the three KIR2DL5N173D-mutant sp-DNFs,
immunohistochemistry revealed no appreciable KIR2DL5
protein expression, whereas human tonsil, normal human
sural nerve, and all NF1-DNFs examined expressed
KIR2DL5 (Figure 2B). To determine whether loss of
KIR2DL5 protein expression correlated with the presence
of a KIR2DL5N173D mutation, we examined two unrelated
tumors (Sp5: basal cell carcinoma, Sp6: keratinous
cyst) isolated from two of the three subjects with this
mutation in their DNFs (Figure 2B). Both non-DNF
tissues were immunopositive for KIR2DL5, suggesting
that KIR2DL5N173D is likely a DNF-specific mutation.
Moreover, in an independent cohort of sp-DNFs, 15/45
tumors were KIR2DL5-immunonegative (33%; Figure
2B, Supplementary Figure 3B), further supporting the
hypothesis that KIR2DL5 expression loss is specific to spDNFs and likely is caused by the KIR2DL5N173D mutation.
To determine whether the KIR2DL5N173D mutation
was responsible for the reduction in KIR2DL5 protein
expression observed, normal human Schwann cells were
infected with either KIR2DL5WT or KIR2DL5N173D viral
expression constructs (Figure 2D). Whereas wild-type
KIR2DL5 expression was easily detected by Western blot
and promoted a minor increase in Schwann cell growth
(1.18-fold increase compared to PLKO-infected Schwann
cells), KIR2DL5N173D mutant-expressing cells exhibited
a 36.9% decrease in KIR2DL5 expression, a 1.88fold increase in cell proliferation (BrdU incorporation)
(Figure 2E), and a 1.5-fold increase in total cell numbers
(Figure 2F) relative to KIR2DL5WT expressing cells.
Together, these data demonstrate that the KIR2DL5N173D
mutation functions in a dominant negative manner to
regulate KIR2DL5 expression and Schwann cell growth.
KIRs were initially discovered on the surface of
natural killer (NK) cells [26], where they have been reported
to mediate the immune response of NK cells and a subset of
T lymphocytes against infection and cancer [27–29]. While
KIR2DL5 is an orphan receptor with no known ligands,
its phosphorylation in NK cells recruits the Src homology
region 2-containing protein tyrosine phosphatase-2
(SHP-2) molecule, resulting in activation of downstream
signaling pathways. Since the role of KIR2DL5 has not
been previously explored in non-immune system cells, we
first demonstrated that KIR2DL5 is expressed in S100β+
Schwann cells within normal human peripheral (sural)
nerve by immunofluorescence (Figure 2C), and in normal
human Schwann cells by western blot (CTL; Figure 2D)
and immunofluorescence (Supplementary Figure 4A).
While the majority of the KIR2DL5 expression in both
normal sural nerve and immunopositive sDNFs was found
in the Schwann cell compartment, there was also expression
in other cell types. In this regard, co-labelling of KIR2DL5+
cells with mast cell (tryptase, c-Kit) and fibroblast
(vimentin)-specific antibodies (Supplementary Figure 4)
revealed that the few remaining KIR2DL5-immunoreactive

RESULTS AND DISCUSSION
In order to identify potential molecular etiologies
for sporadic DNFs (sp-DNFs), we examined a cohort
of 17 male patients (7 NF1-DNFs and 10 sp-DNFs) by
whole-exome sequencing. Using this approach, NF1
gene mutations were detected in 5/7 NF1-DNFs, and
surprisingly, 1/10 (Sp7) sp-DNFs where the identified
point mutation is predicted to result in a splicing variant
of the NF1 transcript (Figure 1A, 1B). The inability
to detect mutations in two of the NF1-DNFs likely
reflects the insensitivity of exome sequencing to identify
intronic mutations or large-gene deletions, both common
mutational types in NF1 [15, 16]. However, consistent with
a clinical diagnosis of NF1 or the presence of a NF1 gene
mutation, immunohistochemical staining confirmed loss
of neurofibromin expression in the Sp7 tumor and in all
NF1-DNFs (Figure 1C, Supplementary Figure 1). Subject
Sp7 was lost to follow-up, and may have undiagnosed
NF1 or harbored a tumor that underwent bi-allelic NF1
gene inactivation [17]. Conversely, all sp-DNFs without an
identified NF1 mutation, as well as an independent cohort
of 45 unrelated sp-DNFs retain neurofibromin expression
(Supplementary Figure 1), consistent with exclusion of
NF1 as a clinical diagnosis.
While 105 genes with exonic nucleotide variations
(frameshift insertions/deletions, missense, and nonsense
mutations; Supplementary Table 1) were identified in more
than one DNF, eight genes were mutated in at least four
DNFs (> 22.22% of the cohort; Figure 1D, Supplementary
Figure 2). These mutated genes did not separate sporadic
or NF1-associated DNFs into clear subgroups; however,
the specific nucleotide alterations identified in 6 of the 8
genes were identical in all of the tumors examined (Figure
1E). Importantly, three of these mutations have also been
reported in other cancers (cBioPortal; www.cbioportal.
org), suggesting potential importance in DNF pathogenesis
that could be pursued beyond the scope of this study.
While no mutations were found in genes commonly
mutated in a related peripheral nerve sheath tumor
(schwannoma; NF2 [18, 19], LZTR1 [20, 21], SMARCB1
[22, 23] genes), recurrent mutations in the KIR2DL5 gene
were identified only in the sp-DNFs (three of nine sp-DNFs
examined). KIR2DL5 is a gene unique to primates, and is
not found in cattle or mice [24]. Of note, the particular
KIR2DL5 mutation (Asn173Asp, N173D; 3/9 tumors)
resulted in a non-conservative change in an evolutionarilyconserved residue (Figure 2A) within a predicted
www.impactjournals.com/oncotarget

47575

Oncotarget

KIR2DL5 expression was also decreased by RNA
(shRNA) interference. Since KIR2DL5 is encoded
by two genes, KIR2DL5A (OMIM: 605305) and
KIR2DL5B (OMIM: 615727) that are > 99% sequence
identical [25], three independently-generated short-

cells in the Sp4, Sp5 and Sp6 DNF tumor specimens were
stromal elements.
As a complementary approach to expressing
the mutant KIR2DL5 gene in normal human Schwann
cells to reduce KIR2DL5 expression, endogenous

Figure 1: NF1 gene mutation and neurofibromin expression stratify DNFs into two subgroups. (A) List of detected NF1
gene mutations and predicted protein alterations. (B) Schematic representation of NF1 gene mutations. (C) Representative images depicting
decreased neurofibromin expression in tumors with NF1 mutations compared to sp-DNFs. Scale bar, 25 µm. (D) Genes recurrently mutated
in more than four DNFs. (E) Recurrent mutations identified in more than four DNFs. Black boxes = mutation.
www.impactjournals.com/oncotarget
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hairpin RNA molecules were employed to target both
genes.
Following Schwann cell infection, 76.78%
(sh#1; TCTCTCCATGACTCACCCTAT), 88.29%
(sh#2; CAGGAGCTCATTTGACATGTA) and 76.32%
(sh#3; GAAACTCTTCAAGTAGTTCAT) KIR2DL5
knockdown was achieved (Figure 3A), leading to 2.2,

3.2- and 2.7-fold increases in cell number, respectively
(direct cell counting; Figure 3B) relative to GFP-vectorinfected cells (CTL). This increase in cell numbers
represented a 2.7- (sh#1), 2.83- (sh#2), and 3- (sh#3)
fold increase in proliferation (BrdU incorporation; Figure
3C), with no change in apoptosis (TUNEL staining;

Figure 2: KIR2DL5N173D mutation reduces KIR2DL5 expression. (A) 3/9 sp-DNFs harbor the KIR2DL5N173D mutation. (B)

KIR2DL5 mutation is associated with decreased KIR2DL5 protein levels in sp-DNFs but not NF1-DNFs or non-DNF tissue. Tonsil and sural
nerve (S.N.) were used as controls. (C) KIR2DL5N173D expression results in reduced KIR2DL5 levels, as demonstrated with a myc antibody
immunoblot of human Schwann cells infected with a myc-tagged KIR2DL5 WT or a KIR2DL5 N173D construct. KIR2DL5N173D expression
results in increased (D) cell proliferation and (E) cell number relative to KIR2DL5WT control-infected Schwann cells. PLKO-GFP-control
(PLKO)-infected cells are shown for comparison. Data are represented as means of three independent infections/over-expression construct
± s.e.m. One-way ANOVA was used for statistical analysis. *p < 0.05; ***p < 0.001. Scale bar 50 μm.
www.impactjournals.com/oncotarget
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Supplementary Figure 3C). Expression of control
KIR2DL5 engineered so as not to be targeted by these
shRNA constructs following shRNA knockdown restored
KIR2DL5 expression, as well as cell proliferation and
cell numbers (Supplementary Figure 3D–3F).
Since RAS-dependent signaling is enhanced in NF1DNFs, the activation status of RAS (RAS-GTP) and RASregulated pathways were examined. Following KIR2DL5
knockdown (KIR2DL5A/BKD), there was a 3.5- (sh#1), 4.7(sh#2), and 2.9- (sh#3) fold increase in RAS activation
(RAS-GTP; Figure 4A). While others have shown that
NF1-DNF growth depends on ERK1/2 pathway activation
[30, 31], KIR2DL5 reduction had no effect on ERK1/2Thr202/
Tyr204
phosphorylation (activation; Supplementary Figure
5A–5D), but rather led to increased AKT activation
(AKTThr308 and AKTSer473 phosphorylation; sh#1, 31.5-fold

and 2.8-fold; sh#2, 19.6-fold and 5.9-fold; sh#3, 15.6fold and 7.3-fold, respectively; n = 3), as well as elevated
mTOR activation (S6Ser240/244 phosphorylation; sh#1, 3.2fold; sh#2, 4.9-fold; sh#3, 7.2-fold; n = 3) (Figure 4A).
Similarly, expression of the mutant KIR2DL5 protein
(KIR2DL5 N173D) resulted in 2.24-fold and 1.78-fold
increases in AKT and S6 phosphorylation, respectively
(Supplementary Figure 3).
To demonstrate that KIR2DL5 regulates cell
proliferation in an AKT/mTOR-dependent fashion, we
initially employed an AKT-specific inhibitor (MK2206).
Following a 4h MK2206 treatment of control- and
shRNA-infected Schwann cells, AKTSer473 phosphorylation
(sh#1, 0.9; sh#2 0.95; sh#3 0.97-fold), as well as the
phosphorylation of two of its downstream effectors S6
(sh#1, 0.4; sh#2 0.6; sh#3 0.5-fold) and PRAS40 (sh#1,

Figure 3: KIR2DL5 is a negative Schwann cell growth regulator. (A) Co-localization of KIR2DL5 with S100β+ Schwann cells

in normal human sural nerve. b. shRNA silencing of KIR2DL5A/B expression in normal human Schwann cells, where KIR2DL5A/BKD cell
KIR2DL5 expression levels were calculated by normalizing the relative KIR2DL5/α-tubulin band intensity ratio to that of GFP-controlinfected Schwann cells. (B) western blot). KIR2DL5A/BKD results in increased (C) cell number and (D) proliferation relative to GFPinfected serum-starved Schwann cells. Data are represented as means of three independent infections/shRNA construct ± s.e.m. One-way
ANOVA with Bonferroni correction was used for statistical analysis. ***p < 0.001. Scale bar 25 μm.
www.impactjournals.com/oncotarget
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0.7; sh#2, 1.3; sh#3, 1.2-fold), were reduced to control
levels (Figure 4B). Additionally, AKT inhibition restored
cell numbers (Figure 4C) and proliferation (Figure 4D)
to normal levels. Next, to determine whether mTOR
inhibition could similarly reverse the effects of KIR2DL5
KD, shRNA-infected Schwann cells were treated with

rapamycin for 4h. Following rapamycin exposure, there
was reduced AKTSer473 phosphorylation (sh#1, 0.7; sh#2
1.1; sh#3 1.2-fold) and S6 phosphorylation (sh#1, 0.8;
sh#2 0.8; sh#3 0.8-fold) (Supplementary Figure 5E),
as well as restoration of cell numbers (Figure 4E) and
proliferation (Figure 4F) to control levels. Collectively,

Figure 4: KIR2DL5A/B is a negative regulator of RAS/AKT signaling. (A) shRNA silencing of KIR2DL5A/B in human Schwann

cells results in increased RAS activity (RAS-GTP), as well as increased AKTThr308 , AKTSer473, and S6Ser240/244, but not ERK1/2Thr202/Tyr204,
phosphorylation relative to GFP-infected Schwann cells. (B) AKTSer473, S6Ser240/244 and PRAS40Thr246 phosphorylation is restored to wild-type
levels following MK2206 treatment of KIR2DL5A/BKD Schwann cells. 4 h MK2206 (C–D) or rapamycin (E–F) treatment restores (C, E)
cell number and (D, F) proliferation of KIR2DL5A/BKD Schwann cells relative to GFP-infected controls. Experiments were repeated at least
three times using independently-derived cell lysates. Data are represented as means ± s.e.m. Two-way ANOVA with Bonferroni correction
was used for statistical analysis. ***p < 0.001.
www.impactjournals.com/oncotarget
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these data establish that KIR2DL5-regulated Schwann
cell growth activates RTK/AKT/mTOR signaling, raising
the intriguing possibility that Sp-DNFs and NF1-DNFs
converge on hyperactivation of the same mitogenic
signaling pathway.
RAS/AKT signaling is typically initiated by receptor
tyrosine kinase (RTK) receptor engagement in Schwann
cells [32–36]. In order to identify this hyperactivated
RTK, a commercially-available human phospho-RTK
array was employed, which recognizes 49 distinct
RTKs (Figure 5A). Whereas the activity of most RTKs
was not significantly altered (n = 48 RTK moieties),
platelet-derived growth factor receptor beta (PDGFRβ)
phosphorylation was elevated (sh#1, 3.5-; sh#2 3.9-; sh#3,
3.5-fold) in KIR2DL5A/BKD Schwann cells relative to
controls. Independent validation of two of these activationspecific phosphorylation sites (PDGFRβTyr771: sh#1, 2-;
sh#2, 4.5-; sh#3, 7.7-fold; and PDGFRβTyr1009: sh#1, 2-;
sh#2, 5.4-; sh#3, 7.3-fold) confirmed receptor activation
in KIR2DL5A/BKD Schwann cells (Figure 5B). Consistent
with a dominant mechanism of action of the KIR2DL5
N173D mutation, there was a 1.84-fold activation of
PDGFRβ in KIR2DL5 N173D-expressing Schwann cells
(Supplementary Figure 3). To determine the necessity
of PDGFRβ activation for KIR2DL5A/BKD-mediated
Schwann cell growth, we employed two different tyrosine
kinase inhibitors that target PDGFRβ activation (imatinib
[37–42] and sunitinib [43]), both of which are currently
in clinical trials for the treatment of NF1-plexiform
neurofibromas (Figure 5C–5F). Incubation of KIR2DL5A/
BKD Schwann cells for 16h with either inhibitor reduced
PDGFRβ and AKT hyperactivation (Figure 5C–5D), as
well as restored total cell numbers (Figure 5E) and cell
proliferation (Figure 5F) to control levels.
While increased PDGFRβ activation was
responsible for AKT-mediated hyperproliferation
following KIR2DL5 loss, the mechanism by which
KIR2DL5 regulates PDGFRβ is not clear. We hypothesize
that KIR2DL5 binds PDGFRβ to restrict its activation.
Consistent with this model, KIR2DL5 binds PDGFRβ
in normal human Schwann cells by PDGFRβ antibodymediated immunoprecipitation. This binding is
ameliorated in KIR2DL5A/BKD Schwann cells, resulting
in a 7.8-fold increase in PDGFRβ binding to PDGFRα
(sh#1, 5.2- ; sh#2, 9.6- ; sh#3, 8.7-fold increase; Figure
5G). As such, KIR2DL5 likely inhibits PDGFRβ through
direct binding, which reduces PDGFR heterodimerization,
PDGFRβ phosphorylation and downstream RAS/AKTmediated Schwann cell growth (Figure 5H).
Taken together, we identified the first mutation
associated with sp-DNFs. This KIR2DL5 N173D mutation
is hypothesized to result in attenuated KIR2DL5 protein
levels, and as such, KIR2DL5 functions as a negative
regulator of Schwann cell proliferation. In this regard,
KIR2DL5 reduction, resulting either from KIR2DL5
knockdown or KIR2DL5 N173D mutation, increases
www.impactjournals.com/oncotarget

Schwann cell growth in a PDGFR/AKT/mTOR-dependent
mechanism. Moreover, these studies provide the first
demonstration that KIR2DL5 can function outside the
immune system. Finally, while the etiologic mechanisms
underlying sp-DNF and NF1-DNF growth control are
distinct, they share a common signaling pathway amenable
to therapeutic targeting.

MATERIALS AND METHODS
Tissue collection and processing
De-identified 10µm-thick sections of formalinfixed paraffin-embedded DNF tissue from 7 male patients
with a confirmed NF1 diagnosis and from 10 male
patients with sp-DNFs were collected from Washington
University Surgical Pathology Department. Total genomic
DNA was extracted following review by an experienced
neuropathologist (S.D.) using a QIAamp DNA FFPE
Tissue Kit (QIAGEN) following manufacturer’s
instructions. Genomic DNA resuspended in elution
buffer was sent for exome sequencing. Since this study
was performed using de-identified dermal neurofibroma
specimens and the patients could not be re-consented,
we were unable to obtain blood for constitutional DNA
analysis.

Whole-exome sequencing and filtering
Whole human exome sequencing was performed
from total genomic DNA of 17 tumors by Otogenetics
Co. Briefly, library preparation was performed using an
Illumina platform. Pair-ended sequencing (100 bp) with
a minimum average coverage of 30x or ~2.7–3Gb was
performed on a HiSeq2500 platform (human exome V5).
Sequence reads were mapped to human reference genome
hg18. Variants were annotated in Annovar and were
filtered in Microsoft Excel to include only the following
criteria: (1) Exonic variations (2) Non-synonymous
variations, stop loss/ stop gain, frameshift insertions
and frameshift deletions (3) 1000 genome, ExAc and
ESP6500 frequencies ≤ 0.01 (4) Deleterious variants
according to SIFT, Polyphen and CADD predictions (5)
Non-common polymorphism in Cosmic and ClinVar
(Supplementary Table 1). Genes mutated more than
twice per tumor or resulting in conservative amino acid
changes were eliminated from further analysis. cBioPortal
for Cancer Genomics (www.cbioportal.org) was used to
search recurrent identified mutations in other cancers. The
complete exome sequencing data is in the process of being
uploaded to dbGaP. The sequence reads were as follows:
Sample
Size
Reads
Sp1
1,016,288,144
9,587,624
Sp2
2,980,285,61
28,115,902
Sp3
4,023,566,444
37,958,174
47580
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Sp4
Sp5
Sp6
Sp7
Sp8
Sp9
Sp10
NF1-1
NF1-2
NF1-3
NF1-4
NF1-5
NF1-6
NF1-7

2,015,092,012
2,763,643,024
2,264,326,420
3,049,257,056
2,111,053,38
850,889,772
4,016,548,608
1,752,023,756
3,296,901,464
2,697,579,372
2,130,578,164
1,632,340,852
1,685,491,160
2,751,629,620

bovine serum (FBS), unless otherwise stated and were
maintained as per the manufacturer’s instructions. For
serum-starvation experiments (Supplementary Figure 5),
Schwann cells were plated on poly-L-lysine-coated plates
in the presence of serum (FBS) for 16h, followed by a 36h
period of serum deprivation during which cells were cultured
only in Schwann cell medium supplemented with Schwann
cell growth factors and Pen/Strep. 10% FBS was added to
the cells for 2, 5, 15, 30 or 60 minutes at which time points
cells were collected for western blotting analysis.
Three sets of lentiviral infection experiments were
performed. Schwann cells were either infected once with
lentivirus particles encoding (1) either a KIR2DL5WT
control or KIR2DL5N173D to establish the effect of the
identified mutation on normal Schwann cells (Figure 2),
(2) either a GFP-control or shKIR2DL5 RNA to knock
down KIR2DL5 expression (Figures 3–5), or were infected
twice with lentiviral preparations encoding (3) both a
GFP control and KIR2DL5CTL control or both shKRI2DL5
RNA and KIR2DL5CTL to confirm the specificity of the
shKIR2DL5 RNA constructs (Supplementary Figure 4).
For all lentiviral infections, HEK-293T cells were initially
cultured in DMEM (Gibco) supplemented with 10%
heat-inactivated FBS and 1% Pen/Strep solution (Gibco).
Three micrograms of total DNA was transfected per well
of a 6-well plate (1.5 µg KIR2DL5WT, KIR2DL5CTL
KIR2DL5N173D, shKIR2DL5 or pLKO-GFP control;
1.5 µg lentiviral packaging constructs) using Fugene
HD reagent (Promega) following manufacturer’s
instructions. 24h post transfection the media was replaced
with fresh Schwann cell media supplemented with10%
FBS, Schwann cell growth factors and antibiotics.
Viral preparations were collected at 48 and 72 h posttransfection, were filtered, supplemented with polybrene
and used for direct infections of Schwann cells. The
sequences of the siRNA constructs were:
shKIR2DL5 #1: TCTCTCCATGACTCACCCTAT;
shKIR2DL5 #2: CAGGAGCTCATTTGACATGTA;
shKIR2DL5 #3: GAAACTCTTCAAGTAGTTCAT;
KIR2DL5WT cDNA cloned in a lentiviral vector was
purchased from Origene and was either directly transfected
into HEK293T cells, or was transfected following sitedirected mutagenesis with QuikChange Site-Directed
mutagenesis kit (Promega) following manufacturer’s
instructions in order to generate KIR2DL5CTL (harboring
six distinct base pair mutations within the short hairpin
recognition sequences but resulting in identical
amino acid sequence) or KIR2DL5N173D. All resulting
constructs were subcloned and sequenced by Genewiz.
The following primers were used to generate the
expression constructs: KIR2DL5CTL1 (Forward: 5′-GA
GCTTGGTTCAGTGGGTGAAGAAGAGCTGCTCGA
GGAATTTCCTGTGACAGAAACAAGCAGTGG-3′,
Reverse: 5′-CCACTGCTTGTTTCTGTCACAGGAAA
TTCCTCGAGCAGCTCTTCTTCACCCACTGAACCA
AGCTC-3′); KIR2DL5CTL2 (Forward: 5′- CCTACACAT

19,010,302
26,072,104
21,361,570
28,766,576
19,915,598
8,027,262
37,891,968
16,528,526
31,102,844
25,448,862
20,099,794
15,399,442
15,900,860
25,958,770

Immunohistochemistry and immunofluorescence
Paraffin-embedded tonsil, 4 normal peripheral
nerves (sural nerve), 23 NF1-DNFs (13 males, 10
females) and 55 sp-DNFs (31 males, 24 females) were
included in the immunohistochemical analyses. All
DNFs were incubated with neurofibromin (Santa Cruz
sc-67) antibodies, while and all DNFs, tonsil and normal
sural nerve sections were incubated with KIR2DL5
(Abcam; ab175895) antibodies. Biotinylated secondary
rabbit antibodies (Vector Laboratories) were used in
combination with Vectastain Elite ABC development
and hematoxylin counterstaining. Normal human
tonsil was used as the reference control tissue for the
KIR2DL5 antibody. Images were acquired on a Nikon
Eclipse E600 microscope conjugated with a Nikon
Plan Fluor 10x/0.30 DIC L objective and a Leica EC3
camera. Normal human sural nerve, sp-DNF sections,
as well as primary cell cultures of normal human
Schwann cells and HEK293T cells were analyzed by
immunofluorescence using S100β (Millipore CB1040),
c-Kit (Millipore; MAB1164), tryptase (Abcam; ab2378),
vimentin (DSHB; AMF-17b) and KIR2DL5 (Abcam;
ab129751) antibodies conjugated to appropriate Alexa
Fluor secondary antibodies. Images were acquired
on a Nikon Eclipse TE300 fluorescence microscope
conjugated with a Nikon Plan Fluor 20x/0.45 ELWD
objective and a Leica DFC3000G camera.

Normal human Schwann cell culture, lentiviral
infection and pharmacological inhibitor
treatments
Normal human Schwann cells (ScienCell Research
Laboratories) were cultured on poly-L-lysine-coated plates
in Schwann cell medium (ScienCell #1701) supplemented
with Schwann cell growth factors, Pen/Strep and fetal
www.impactjournals.com/oncotarget
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Figure 5: KIR2DL5A/B inhibits Schwann cell proliferation in a PDGFRβ/AKT-dependent manner. (A) PDGFRβ is

hyperphosphorylated following silencing of KIR2DL5 in normal human Schwann cells as demonstrated with a human phospho-RTK array.
(B) PDGFRβTyr771 and PDGFRβTyr1009 phosphorylation is increased following KIR2DL5A/B silencing. Inhibition of aberrant PDGFRβ and
AKT phosphorylation following 16 h imatinib (C) or sunitinib (D) treatment restores cell numbers (E) and proliferation (F) to control
levels. Data are represented as means ± s.e.m. All experiments were repeated at least three times. Two-way ANOVA with Bonferroni
correction was used for statistical analysis. ***p < 0.001 compared to vehicle control, p < 0.001 compared to vehicle sh#1, sh#2, sh#3,
respectively. (G) KIR2DL5A/B silencing leads to increased PDGFRβ/PDGFRα binding, as assessed by immunoprecipitation. (H) The
proposed model of KIR2DL5 growth regulation envisions that KIR2DL5 normally binds and sequesters PDGFRβ, such that KIR2DL5 loss
leads to increased PDGFRα/β binding and RAS/AKT-mediated hyperproliferation.
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GCTTCGGCTCGTTACATGATTCACCGTACGAGTG
GTCAGACCCGAGTG-3′, Reverse: 5-CACTCGG
GTCTGACCACTCGTACGGTGAATCATGTAACGAGC
CGAAGCATGTGTAGG-3′); KIR2DL5N173D (Forward:
5′-CCTGGAATGTTCCATCGACGCTGGGCACTGC-3′;
Reverse: 5′-GCAGTGCCCAGCGTCGATGGAACAT
TCCAGG-3′).
GFP control- or siRNA-infected Schwann cells
underwent treatment with the following reagents: MK2206
(50nM in DMSO, 4 h; Selleckchem), rapamycin (10μM
in DMSO, 4 h; Selleckchem), imatinib (10 μM in water,
16h; Sigma), sunitinib (10 μM in DMSO, 16 h; Sigma), or
PD0325901 (10 nM in DMSO, 4h; Selleckchem).

manufacturer’s instructions (RAS activation kit; Millipore).
All experiments were repeated at least three times using
independently derived cell lysates.

Proliferation and apoptosis assays
Schwann cell proliferation and TUNEL staining
were assessed using the BrdU Cell Proliferation
Colorimetric ELISA kit (Roche) or the TUNEL staining
kit (Roche) following manufacturer’s instructions. For
both assays, Schwann cells were seeded at 5000 cells/ well
of a 96-well plate. For the proliferation assays, Schwann
cells were serum-starved for 24 hours, if treated, incubated
in vehicle or appropriate inhibitors for a total of 24 hours,
labelled with BrdU for 18 h followed by 90min incubation
in peroxidase-conjugated anti-BrdU antibody. The optical
density of the cells was measured at 405 nm on a BioRad spectrophotometer. For the TUNEL assay, cells were
incubated in serum-containing media for 24 h before being
fixed in 4% PFA, incubated in TUNEL substrate for 1 h
and imaged using a fluorescent microscope.

Western blotting, immunoprecipitation, RTK
arrays and RAS/RAS pathway activity assays
Western blotting was performed on Schwann
cells lysed in buffer containing 1% NP-40 (nonyl
phenoxypolyethoxylethanol), supplemented with protease
and phosphatase inhibitors using KIR2DL5 (Abcam), α–
tubulin (Sigma), RAS (Millipore), phospho-AKTThr308,
phospho-AKTSer473, AKT, phospho-S6Ser240/244, S6, phosphoErk1/2Thr202/204, Erk1/2, phosphoPRAS40Thr246, PRAS40,
phospho-PDGFRβTyr771, phospho-PDGFRβTyr1009, PDGFRβ,
PDGFRα (Cell Signaling) primary antibodies, as well as
HRP-conjugated secondary antibodies (Cell Signaling)
and ECL (Fisher) chemiluminescence. Western signal band
intensity was quantified using ImageJ Software (National
Institutes of Health, USA, http://imagej.nih.gov/ij Java
1.7.0_67). KIR2DL5A/BKD cell KIR2DL5 expression levels
(Figures 2A, 3D) were calculated by normalizing the relative
KIR2DL5/α-tubulin band intensity ratio to that of GFPcontrol-infected Schwann cells. For the immunoprecipitation
studies, 100 μg total Schwann cell protein lysate was precleared for 1h in agarose protein G beads (Cell Signaling),
immunoprecipitated with PDGFRβ overnight and collected
with agarose protein G beads for 2 hours. For the human
phospho-RTK array (human phospho-receptor tyrosine
kinase array kit; R&D Systems) Schwann cells were lysed
in the provided buffer and 80μg total protein was assayed
using manufacturer’s instructions. In brief, the assay can
detect phosphorylation of the following RTKs: ALK/
CD246, EphB4, MuSK, Axl, EphB6, PDGFRα, DDR1,
ErbB2, PDGFRβ, DDR2, ErbB3, c-Ret, Dtk, ErbB4, ROR1,
EGFR, FGFR1, ROR2, EphA1, FGFR2α, Ryk, EphA2,
FGFR3, SCFR/c-kit, EphA3, FGFR4, Tie-1, EphA4, Flt3/Flk-2, Tie-2, EphA5, HGFR/c-MET, TrkA, EphA6,
IGF1R, TrkB, EphA7, Insulin R/CD220, TrkC, EphA10,
M-CSFR, VEGFR1/Flt-1, EphB1, Mer, VEGFR2/KDR,
EphB2, MSPR/Ron, VEGFR3/Flt-4, and EphB3. Since
only PDGFRβ was hyperphosphorylated, the activation
was independently validated with two separate phosphoPDGFRβ antibodies: phospho-PDGFRβTyr771, phosphoPDGFRβTyr1009 (Cell Signaling). RAS activity assays were
performed following Raf1-RBD immunoprecipitation using
www.impactjournals.com/oncotarget

Statistical analyses
All statistical tests were performed using GraphPad
Prism 5 software. Student’s t-test, one-way or two-way
analysis of variance (ANOVA) with Bonferroni post-test
correction was employed for all experiments.
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